This is a news story, published by Yahoo Finance, that relates primarily to BNT111 news.
For more BNT111 news, you can click here:
more BNT111 newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
cancer drug candidate BNT111. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest cancer drug development news, advanced melanoma news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
mRNA immunotherapy candidate BNT111Reuters
•84% Informative
COVID-19 vaccine maker BioNTech's cancer drug candidate BNT111 showed significant improvement in the response rate in patients with advanced melanoma during a Phase 2 trial.
The German company said in March it was shifting its focus towards cancer drug development, as it adjusts to the decline in its vaccine business.
VR Score
93
Informative language
98
Neutral language
89
Article tone
formal
Language
English
Language complexity
78
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links